{"status":"ok","message-type":"work","message-version":"1.0.0","message":{"indexed":{"date-parts":[[2026,10,2]],"date-time":"2026-10-02T20:13:41Z","timestamp":1790972021119,"version":"4.1.0"},"reference-count":57,"publisher":"Frontiers Media SA","license":[{"start":{"date-parts":[[2024,2,26]],"date-time":"2024-02-26T00:00:00Z","timestamp":1708905600000},"content-version":"vor","delay-in-days":0,"URL":"https:\/\/creativecommons.org\/licenses\/by\/4.0\/"}],"content-domain":{"domain":["frontiersin.org"],"crossmark-restriction":true},"short-container-title":["Front. Immunol."],"abstract":"<jats:sec><jats:title>Background<\/jats:title><jats:p>Metabolic dysfunction-associated steatotic liver disease (MASLD), previously non-alcoholic fatty liver disease (NAFLD), is a leading cause of chronic liver disease worldwide. In 20%\u201330% of MASLD patients, the disease progresses to metabolic dysfunction-associated steatohepatitis (MASH, previously NASH) which can lead to fibrosis\/cirrhosis, liver failure as well as hepatocellular carcinoma (HCC). Here we investigated the role of histidine-rich glycoprotein (HRG), a plasma protein produced by hepatocytes, in MASLD\/MASH progression and HCC development.<\/jats:p><\/jats:sec><jats:sec><jats:title>Methods<\/jats:title><jats:p>The role of HRG was investigated by morphological, cellular, and molecular biology approaches in (a) HRG <jats:italic>knock-out<\/jats:italic> mice (HRG<jats:sup>\u2212\/\u2212<\/jats:sup> mice) fed on a CDAA dietary protocol or a MASH related diethyl-nitrosamine\/CDAA protocol of hepatocarcinogenesis, (b) THP1 monocytic cells treated with purified HRG, and (c) well-characterized cohorts of MASLD patients with or without HCC.<\/jats:p><\/jats:sec><jats:sec><jats:title>Results<\/jats:title><jats:p>In non-neoplastic settings, murine and clinical data indicate that HRG increases significantly in parallel with disease progression. In particular, in MASLD\/MASH patients, higher levels of HRG plasma levels were detected in subjects with extensive fibrosis\/cirrhosis. When submitted to the pro-carcinogenic protocol, HRG<jats:sup>\u2212\/\u2212<\/jats:sup> mice showed a significant decrease in the volume and number of HCC nodules in relation to decreased infiltration of macrophages producing pro-inflammatory mediators, including IL-1\u03b2, IL-6, IL-12, IL-10, and VEGF as well as impaired angiogenesis. The histopathological analysis (H-score) of MASH-related HCC indicate that the higher HRG positivity in peritumoral tissue significantly correlates with a lower overall patient survival and an increased recurrence. Moreover, a significant increase in HRG plasma levels was detected in cirrhotic (F4) patients and in patients carrying HCC vs. F0\/F1 patients.<\/jats:p><\/jats:sec><jats:sec><jats:title>Conclusion<\/jats:title><jats:p>Murine and clinical data indicate that HRG plays a significant role in MASLD\/MASH progression to HCC by supporting a specific population of tumor-associated macrophages with pro-inflammatory response and pro-angiogenetic capabilities which critically support cancer cell survival. Furthermore, our data suggest HRG as a possible prognostic predictor in HCC patients with MASLD\/MASH-related HCCs.<\/jats:p><\/jats:sec>","DOI":"10.3389\/fimmu.2024.1342404","type":"journal-article","created":{"date-parts":[[2024,2,26]],"date-time":"2024-02-26T04:37:36Z","timestamp":1708922256000},"update-policy":"https:\/\/doi.org\/10.3389\/crossmark-policy","source":"Crossref","is-referenced-by-count":15,"title":["Histidine-rich glycoprotein in metabolic dysfunction-associated steatohepatitis-related disease progression and liver carcinogenesis"],"prefix":"10.3389","volume":"15","author":[{"given":"Beatrice","family":"Foglia","sequence":"first","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Salvatore","family":"Sutti","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Stefania","family":"Cannito","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Chiara","family":"Rosso","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Marina","family":"Maggiora","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Alice","family":"Casalino","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Claudia","family":"Bocca","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Erica","family":"Novo","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Francesca","family":"Protopapa","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Naresh Naik","family":"Ramavath","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Alessia","family":"Provera","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Alessandro","family":"Gambella","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Elisabetta","family":"Bugianesi","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Frank","family":"Tacke","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Emanuele","family":"Albano","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Maurizio","family":"Parola","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]}],"member":"1965","published-online":{"date-parts":[[2024,2,26]]},"reference":[{"key":"B1","doi-asserted-by":"publisher","DOI":"10.1016\/j.jhep.2023.06.003","article-title":"NAFLD Nomenclature consensus group, 2023. A multi-society Delphi consensus statement on new fatty liver disease nomenclature","volume":"79","author":"Rinella","year":"2023","journal-title":"J Hepatol"},{"key":"B2","doi-asserted-by":"publisher","DOI":"10.1038\/nrgastro.2013.171","article-title":"The global NAFLD epidemic","volume":"10","author":"Loomba","year":"2013","journal-title":"Nat Rev Gastroenterol Hepatol"},{"key":"B3","doi-asserted-by":"publisher","first-page":"73","DOI":"10.1002\/hep.28431","article-title":"Global epidemiology of nonalcoholic fatty liver disease-Meta-analytic assessment of prevalence, incidence, and outcomes","volume":"64","author":"Younossi","year":"2016","journal-title":"Hepatology"},{"key":"B4","doi-asserted-by":"publisher","first-page":"11","DOI":"10.1038\/nrgastro.2017.109","article-title":"Global burden of NAFLD and NASH: trends, predictions, risk factors and prevention","volume":"15","author":"Younossi","year":"2018","journal-title":"Nat Rev Gastroenterol Hepatol"},{"key":"B5","doi-asserted-by":"publisher","DOI":"10.1002\/hep.30251","article-title":"Global perspectives on nonalcoholic fatty liver disease and nonalcoholic steatohepatitis","volume":"69","author":"Younossi","year":"2019","journal-title":"Hepatology"},{"key":"B6","doi-asserted-by":"publisher","DOI":"10.1016\/j.cld.2023.01.001","article-title":"Nonalcoholic fatty liver disease: disease burden and disease awareness","volume":"27","author":"Golabi","year":"2023","journal-title":"Clin Liver Dis"},{"key":"B7","doi-asserted-by":"publisher","first-page":"896","DOI":"10.1016\/j.jhep.2018.05.036","article-title":"Modeling NAFLD disease burden in China, France, Germany, Italy, Japan, Spain, United Kingdom, and United States for the period 2016-2030","volume":"69","author":"Estes","year":"2018","journal-title":"J Hepatol"},{"key":"B8","doi-asserted-by":"publisher","DOI":"10.2337\/diabetes.50.8.1844","article-title":"Non-alcoholic fatty liver disease: a feature of the metabolic syndrome","volume":"50","author":"Marchesini","year":"2001","journal-title":"Diabetes"},{"key":"B9","doi-asserted-by":"publisher","DOI":"10.1002\/hep.23784","article-title":"NASH Clinical Research Network NASH Clinical Research Network, 2010. Clinical, laboratory and histological associations in adults with nonalcoholic fatty liver disease","volume":"52","author":"Neuschwander-Tetri","year":"2010","journal-title":"Hepatology"},{"key":"B10","doi-asserted-by":"publisher","DOI":"10.1002\/hep.29367","article-title":"The diagnosis and management of nonalcoholic fatty liver disease: Practice guidance from the American Association for the Study of Liver Diseases","volume":"67","author":"Chalasani","year":"2018","journal-title":"Hepatology"},{"key":"B11","doi-asserted-by":"publisher","first-page":"22","DOI":"10.1016\/j.cmet.2017.08.002","article-title":"Nonalcoholic fatty liver disease as a nexus of metabolic and hepatic diseases","volume":"27","author":"Samuel","year":"2018","journal-title":"Cell Metab"},{"key":"B12","doi-asserted-by":"publisher","first-page":"e00112","DOI":"10.1002\/edm2.112","article-title":"The metabolic basis of nonalcoholic steatohepatitis","volume":"3","author":"Chakravarthy","year":"2020","journal-title":"Endocrinol Diabetes Metab"},{"key":"B13","doi-asserted-by":"publisher","first-page":"440","DOI":"10.1016\/j.cgh.2014.09.046","article-title":"Diagnostic performance of magnetic resonance elastography in staging liver fibrosis: a systematic review and meta-analysis of individual participant data","volume":"13","author":"Singh","year":"2015","journal-title":"Clin Gastroenterol Hepatol"},{"key":"B14","doi-asserted-by":"publisher","DOI":"10.1055\/s-0035-1562943","article-title":"Epidemiology and natural history of nonalcoholic fatty liver disease","volume":"35","author":"Satapathy","year":"2015","journal-title":"Semin Liver Dis"},{"key":"B15","doi-asserted-by":"publisher","DOI":"10.1016\/j.jhep.2014.11.034","article-title":"Evidence of NAFLD progression from steatosis to fibrosing-steatohepatitis using paired biopsies: implications for prognosis and clinical management","volume":"62","author":"McPherson","year":"2015","journal-title":"J Hepatol"},{"key":"B16","doi-asserted-by":"publisher","DOI":"10.1002\/hep.30946","article-title":"The 20% Rule of NASH progression: the natural history of advanced fibrosis and cirrhosis due to NASH","volume":"70","author":"Loomba","year":"2019","journal-title":"Hepatology"},{"key":"B17","doi-asserted-by":"publisher","DOI":"10.1016\/S0140-6736(20)32511-3","article-title":"Non-alcoholic fatty liver disease","volume":"397","author":"Powell","year":"2021","journal-title":"Lancet"},{"key":"B18","doi-asserted-by":"publisher","first-page":"197","DOI":"10.1016\/j.cell.2009.12.052","article-title":"Dietary and genetic obesity promote liver inflammation and tumorigenesis by enhancing IL-6 and TNF expression","volume":"140","author":"Park","year":"2010","journal-title":"Cell"},{"key":"B19","doi-asserted-by":"publisher","DOI":"10.1038\/s41575-020-00381-6","article-title":"Global epidemiology of NAFLD-related HCC: trends, predictions, risk factors and prevention","volume":"18","author":"Huang","year":"2021","journal-title":"Nat Rev Gastroenterol Hepatol"},{"key":"B20","doi-asserted-by":"publisher","DOI":"10.3322\/caac.21660","article-title":"Global cancer statistics 2020: GLOBOCAN estimates of incidence and mortality worldwide for 36 cancers in 185 countries","volume":"71","author":"Sung","year":"2021","journal-title":"CA Cancer J Clin"},{"key":"B21","doi-asserted-by":"publisher","DOI":"10.1016\/j.cgh.2020.05.064","article-title":"Nonalcoholic steatohepatitis is the fastest growing cause of hepatocellular carcinoma in liver transplant candidates","volume":"17","author":"Younossi","year":"2019","journal-title":"Clin Gastroenterol Hepatol"},{"key":"B22","doi-asserted-by":"publisher","DOI":"10.1002\/hep.32228","article-title":"Global Burden of Non-alcoholic Fatty Liver Disease (NAFLD) and chronic liver disease (CLD) Among Adolescents and Young Adults","volume":"75","author":"Paik","year":"2022","journal-title":"Hepatology"},{"key":"B23","doi-asserted-by":"publisher","DOI":"10.1002\/mc.20691","article-title":"Exploring genomic profiles of hepatocellular carcinoma","volume":"50","author":"Woo","year":"2011","journal-title":"Mol Carcinog"},{"key":"B24","doi-asserted-by":"publisher","first-page":"26","DOI":"10.1055\/s-0038-1676806","article-title":"Inflammation and liver cancer: molecular mechanisms and therapeutic targets","volume":"39","author":"Yang","year":"2019","journal-title":"Semin Liver Dis"},{"key":"B25","doi-asserted-by":"publisher","DOI":"10.1016\/j.cell.2021.04.015","article-title":"Mechanisms and disease consequences of nonalcoholic fatty liver disease","volume":"184","author":"Loomba","year":"2021","journal-title":"Cell"},{"key":"B26","doi-asserted-by":"publisher","DOI":"10.3390\/cancers13040730","article-title":"Inflammatory mechanisms underlying nonalcoholic steatohepatitis and the transition to hepatocellular carcinoma","volume":"13","author":"Peiseler","year":"2021","journal-title":"Cancers"},{"key":"B27","doi-asserted-by":"publisher","first-page":"487","DOI":"10.1038\/s41575-023-00754-7","article-title":"Nonalcoholic steatohepatitis-related hepatocellular carcinoma: pathogenesis and treatment","volume":"20","author":"Llovet","year":"2023","journal-title":"Nat Rev Gastroenterol Hepatol"},{"key":"B28","doi-asserted-by":"publisher","DOI":"10.1038\/s41575-023-00807-x","article-title":"Hepatic inflammatory responses in liver fibrosis","volume":"20","author":"Hammerich","year":"2023","journal-title":"Nat Rev Gastroenterol Hepatol"},{"key":"B29","doi-asserted-by":"publisher","DOI":"10.1046\/j.1440-1711.2000.00940.x","article-title":"Murine histidine-rich glycoprotein: cloning, characterization and cellular origin","volume":"78","author":"Hulett","year":"2000","journal-title":"Immunol Cell Biol"},{"key":"B30","doi-asserted-by":"publisher","DOI":"10.1016\/j.biochi.2015.09.024","article-title":"Structure-function relationships in mammalian histidine-proline-rich glycoprotein","volume":"118","author":"Ronca","year":"2015","journal-title":"Biochimie"},{"key":"B31","doi-asserted-by":"publisher","DOI":"10.1016\/j.gendis.2020.07.015","article-title":"Histidine-rich glycoprotein (HRGP): Pleiotropic and paradoxical effects on macrophage, tumor microenvironment, angiogenesis, and other physiological and pathological processes","volume":"9","author":"Pan","year":"2022","journal-title":"Genes Dis"},{"key":"B32","doi-asserted-by":"publisher","DOI":"10.1172\/JCI112435","article-title":"Interaction of histidine-rich glycoprotein with fibrinogen and fibrin","volume":"77","author":"Leung","year":"1986","journal-title":"J Clin Invest"},{"key":"B33","doi-asserted-by":"publisher","DOI":"10.1007\/s12016-007-8058-6","article-title":"Histidine-rich glycoprotein modulation of immune\/autoimmune, vascular, and coagulation systems","volume":"34","author":"Blank","year":"2008","journal-title":"Clin Rev Allergy Immunol"},{"key":"B34","doi-asserted-by":"publisher","first-page":"31","DOI":"10.1016\/j.ccr.2010.11.009","article-title":"HRG inhibits tumor growth and metastasis by inducing macrophage polarization and vessel normalization through downregulation of PlGF","volume":"19","author":"Rolny","year":"2011","journal-title":"Cancer Cell"},{"key":"B35","doi-asserted-by":"publisher","DOI":"10.1002\/hep.28418","article-title":"Histidine-rich glycoprotein promotes macrophage activation and inflammation in chronic liver disease","volume":"63","author":"Bartneck","year":"2016","journal-title":"Hepatology"},{"key":"B36","doi-asserted-by":"publisher","DOI":"10.1002\/hep.29754","article-title":"Hypoxia-inducible factor 2\u03b1 drives nonalcoholic fatty liver progression by triggering hepatocyte release of histidine-rich glycoprotein","volume":"67","author":"Morello","year":"2018","journal-title":"Hepatology"},{"key":"B37","doi-asserted-by":"publisher","DOI":"10.1158\/0008-5472.CAN-11-2194","article-title":"Genetic deficiency in plasma protein HRG enhances tumor growth and metastasis by exacerbating immune escape and vessel abnormalization","volume":"72","author":"Tugues","year":"2012","journal-title":"Cancer Res"},{"key":"B38","doi-asserted-by":"publisher","DOI":"10.18632\/oncotarget.4997","article-title":"Histidine-rich glycoprotein function in hepatocellular carcinoma depends on its N-glycosylation status, and it regulates cell proliferation by inhibiting Erk1\/2 phosphorylation","volume":"6","author":"Zhang","year":"2015","journal-title":"Oncotarget"},{"key":"B39","doi-asserted-by":"publisher","DOI":"10.7150\/thno.47286","article-title":"HRG switches TNFR1-mediated cell survival to apoptosis in Hepatocellular Carcinoma","volume":"10","author":"Zou","year":"2020","journal-title":"Theranostics"},{"key":"B40","doi-asserted-by":"publisher","DOI":"10.1002\/ijc.29312","article-title":"The nuclear bile acid receptor FXR controls the liver derived tumor suppressor histidine-rich glycoprotein","volume":"136","author":"Deuschle","year":"2015","journal-title":"Int J Cancer"},{"key":"B41","doi-asserted-by":"publisher","first-page":"203","DOI":"10.3390\/toxins12030203","article-title":"Molecular mechanism of aflatoxin-induced hepatocellular carcinoma derived from a bioinformatics analysis","volume":"12","author":"Cai","year":"2020","journal-title":"Toxins (Basel)"},{"key":"B42","doi-asserted-by":"publisher","DOI":"10.1016\/j.jcmgh.2021.10.002","article-title":"Hepatocyte-specific deletion of HIF2\u03b1 Prevents NASH-related liver carcinogenesis by decreasing cancer cell proliferation","volume":"13","author":"Foglia","year":"2022","journal-title":"Cell Mol Gastroenterol Hepatol"},{"key":"B43","doi-asserted-by":"publisher","DOI":"10.21769\/BioProtoc.3465","article-title":"Semi-quantitative determination of protein expression using immunohistochemistry staining and analysis: an integrated protocol","volume":"9","author":"Crowe","year":"2019","journal-title":"Bio-protocol"},{"key":"B44","doi-asserted-by":"publisher","DOI":"10.1016\/j.humpath.2011.07.005","article-title":"The steatohepatitic variant of hepatocellular carcinoma and its association with underlying steatohepatitis","volume":"43","author":"Salomao","year":"2012","journal-title":"Hum Pathol"},{"key":"B45","doi-asserted-by":"publisher","first-page":"644","DOI":"10.1016\/j.molcel.2019.07.028","article-title":"Landscape of intercellular crosstalk in healthy and NASH liver revealed by single-cell secretome gene analysis","volume":"75","author":"Xiong","year":"2019","journal-title":"Mol Cell"},{"key":"B46","doi-asserted-by":"publisher","DOI":"10.3389\/fimmu.2022.848367","article-title":"Integrated analysis highlights the immunosuppressive role of TREM2+ Macrophages in hepatocellular carcinoma","volume":"13","author":"Zhou","year":"2022","journal-title":"Front Immunol"},{"key":"B47","doi-asserted-by":"publisher","DOI":"10.1016\/j.jhepr.2022.100557","article-title":"The ALBI score: From liver function in patients with HCC to a general measure of liver function","volume":"4","author":"Toyoda","year":"2022","journal-title":"JHEP Rep"},{"key":"B48","doi-asserted-by":"publisher","DOI":"10.3389\/fimmu.2023.1257596","article-title":"Macrophage metabolism in nonalcoholic fatty liver disease","volume":"14","author":"Zhang","year":"2023","journal-title":"Front Immunol"},{"key":"B49","doi-asserted-by":"publisher","DOI":"10.1016\/j.jcmgh.2023.03.002","article-title":"The multifaceted roles of macrophages in NAFLD pathogenesis","volume":"15","author":"Vonderlin","year":"2023","journal-title":"Cell Mol Gastroenterol Hepatol"},{"key":"B50","doi-asserted-by":"publisher","first-page":"549e555","DOI":"10.1016\/s1471-4906(02)02302-5","article-title":"Macrophage polarization: tumor-associated macrophages as a paradigm for polarized M2 mononuclear phagocytes","volume":"23","author":"Mantovani","year":"2002","journal-title":"Trends Immunol"},{"key":"B51","doi-asserted-by":"crossref","first-page":"231e237","DOI":"10.1016\/j.coi.2010.01.009","article-title":"Macrophages, innate immunity and cancer: balance, tolerance, and diversity","volume":"22","author":"Mantovani","year":"2010","journal-title":"Curr Opin Immunol"},{"key":"B52","doi-asserted-by":"publisher","DOI":"10.18926\/AMO\/62805","article-title":"Multiple roles of histidine-rich glycoprotein in vascular homeostasis and angiogenesis","volume":"75","author":"Gao","year":"2021","journal-title":"Acta Med Okayama"},{"key":"B53","doi-asserted-by":"publisher","first-page":"45","DOI":"10.1172\/JCI9061","article-title":"Histidine-rich glycoprotein inhibits the antiangiogenic effect of thrombospondin-1","volume":"107","author":"Simantov","year":"2001","journal-title":"J Clin Invest"},{"key":"B54","doi-asserted-by":"crossref","first-page":"27","DOI":"10.1016\/j.matbio.2004.11.005","article-title":"The antiangiogenic effect of thrombospondin-2 is mediated by CD36 and modulated by histidine rich glycoprotein","volume":"24","author":"Simantov","year":"2005","journal-title":"Matrix Biol"},{"key":"B55","doi-asserted-by":"publisher","DOI":"10.1074\/jbc.270.7.2981","article-title":"Recombinant GST\/CD36 fusion proteins define a thrombospondin binding domain. Evidence for a single calcium dependent binding site on CD36","volume":"270","author":"Pearce","year":"1995","journal-title":"J Biol Chem"},{"key":"B56","doi-asserted-by":"publisher","DOI":"10.2353\/ajpath.2010.090782","article-title":"Histidine-rich glycoprotein modulates the anti-angiogenic effects of vasculostatin","volume":"176","author":"Klenotic","year":"2010","journal-title":"Am J Pathol"},{"key":"B57","doi-asserted-by":"publisher","DOI":"10.1371\/journal.pone.0040033","article-title":"Context-dependent role of the CD36 \u2013 thrombospondin - histidine-rich glycoprotein axis in tumor angiogenesis and growth","volume":"7","author":"Hale","year":"2017","journal-title":"PlosOne"}],"container-title":["Frontiers in Immunology"],"original-title":[],"link":[{"URL":"https:\/\/www.frontiersin.org\/articles\/10.3389\/fimmu.2024.1342404\/full","content-type":"unspecified","content-version":"vor","intended-application":"similarity-checking"}],"deposited":{"date-parts":[[2024,2,26]],"date-time":"2024-02-26T04:37:41Z","timestamp":1708922261000},"score":1,"resource":{"primary":{"URL":"https:\/\/www.frontiersin.org\/articles\/10.3389\/fimmu.2024.1342404\/full"}},"subtitle":[],"short-title":[],"issued":{"date-parts":[[2024,2,26]]},"references-count":57,"alternative-id":["10.3389\/fimmu.2024.1342404"],"URL":"https:\/\/doi.org\/10.3389\/fimmu.2024.1342404","relation":{},"ISSN":["1664-3224"],"issn-type":[{"value":"1664-3224","type":"electronic"}],"subject":[],"published":{"date-parts":[[2024,2,26]]},"article-number":"1342404"}}